Abstract: A bi-directional penetrating metal bottleneck structure of a type IV hydrogen storage tank is provided, which includes a metal valve seat, a plastic liner, and a fiber winding layer. A valve seat hole is formed on an inner side of the metal valve seat, and the metal valve seat includes an annular flange, a valve seat column section, and a valve seat extension. L-shaped through holes and radial penetrating holes are formed in the valve seat column section. The valve seat hole is an irregular through hole and is provided with an annular groove. The valve seat extension is provided with a winding inclined plane, a self-tightening conical surface, a circumferential groove, and axial penetrating holes. The plastic liner includes an inner plastic joint, an outer plastic joint, a tapered connecting section, L-shaped connectors, radial connectors, axial connectors, and a reinforcement section.

Abstract: The present invention discloses an anti-NKp30 single domain antibody capable of activating the release of cytokines from NK cells or ??T cells, and a nucleic acid encoding the anti-NKp30 single domain antibody. The present invention also discloses a multifunctional fusion protein comprising the anti-NKp30 single domain antibody and a composition thereof, and the use in drugs for the treatment, prevention or diagnosis of diseases.

Abstract: Disclosed is a nanocomplex, a preparation method therefor, and a use thereof. The nanocomplex comprises 0-60% a protein drug, 0.03-15% hyaluronic acid, 0.8-20% protamine, 35-95% lipid components, and 2.5-40% a apolipoprotein and/or a mimetic peptide thereof; the lipid components comprise an electrically neutral lipid and an anionic lipid; and the total amount of hyaluronic acid and protamine is 0.03-15%. The nanocomplex of the present invention provides a general-type carrier for protein drugs having different physicochemical properties (such as molecular weights of 10-255 KDa and PIs of 4-11), implements highly efficient intracellular, in vivo, and even in-brain delivery, utilized technology is universal in nature, and said invention can effectively solve the current problem of insufficient in vivo and in vitro transport of protein drugs (comprising a protein drug exceeding the molecular weight and PI of an embodiment).

Abstract: The present invention relates to a pyrazole compound and a preparation method therefor and a use thereof. In particular, the present invention relates to a compound shown in Formula I, a pharmaceutical composition containing same or a pharmaceutically acceptable form thereof, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof.

Abstract: A multifunctional antibody acquired via a genetic engineering technique, targeting PD-1 and, at the same time, providing biological effects of an IL-15/IL-15R? complex, a nucleic acid molecule encoding the antibody, a recombinant vector comprising the nucleic acid molecule, a recombinant cell comprising the recombinant vector, a preparation method for the multifunctional antibody, and medicinal uses thereof. The multifunctional antibody effectively solves drug resistance against a single target antibody medicament and relapse, also reduces the effective dose, kills tumor cells more effectively, and extends the survival period of in situ tumor model animals; and, compared with an IL-15 or IL-15/IL-15 receptor complex, extends the serum half-life, increases tumor targeting, and reduces toxic and side effects.